Even though there have been attempts to develop targeted therapies for glioblastoma, such as EGFR and VEGFR inhibitors erlotinib (28) and tivozanib (29), to date there is no effective treatment for this cancer and development of drug resistance is one of the major problems with current therapies (30). The gene discussed is EGFR; the disease is cancer.